Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Krystal Biotech filings document formal disclosures for a commercial-stage biotechnology company developing and commercializing genetic medicines. Recent 8-K reports furnish quarterly and annual financial results, VYJUVEK net product revenue updates, Regulation FD clinical materials, FDA-related program updates, and commercial launch information for VYJUVEK in Japan.
The company's proxy materials disclose board and shareholder-vote matters, executive compensation, equity awards, ownership information, and governance practices. Together, the filings record how Krystal reports operating performance, capital resources, pipeline and regulatory disclosures, and public-company governance for its HSV-1-based gene therapy platform.
Krystal Biotech, Inc. (KRYS) reported that director Dino A. Rossi received new equity awards on September 14, 2026. He was granted options to purchase 1,187 shares of common stock at an exercise price of $340.03 per share, expiring on September 13, 2036, which vest in full on September 14, 2027, subject to continued service on the Board and earlier vesting conditions under the company's Non-Employee Director Compensation Policy. He also received 471 restricted stock units, each representing a contingent right to one share of common stock, which vest in full on September 14, 2027 under the same service and policy conditions.
Krystal Biotech, Inc. (symbol: KRYS) is the issuer of record for a Form 4 filing submitted to the SEC. Sutherland Everett Rand reported acquisition or exercise transactions in this Form 4 filing.
Krystal Biotech, Inc. (KRYS) reported that director Everett Rand Sutherland received equity awards on September 14, 2026. He was granted 1,187 stock options to buy common stock at $340.03 per share, vesting in full on September 14, 2027, and 471 restricted stock units, also vesting in full on that date, in each case subject to continued Board service and earlier vesting conditions under the company’s Non-Employee Director Compensation Policy.
Krystal Biotech, Inc. (symbol: KRYS) is the issuer of record for a Form 4 filing submitted to the SEC. Mazzacco Catherine reported acquisition or exercise transactions in this Form 4 filing.
Krystal Biotech, Inc. (KRYS) reported that director Catherine Mazzacco received equity awards on September 14, 2026. She was granted 1,187 stock options to buy common stock at $340.03 per share, expiring on September 13, 2036, and 471 restricted stock units. Both awards vest in full on September 14, 2027, subject to her continued service on the board and potential earlier vesting under the company’s Non-Employee Director Compensation Policy. No Rule 10b5-1 trading plan is reported for these awards.
Krystal Biotech, Inc. (symbol: KRYS) is the issuer of record for a Form 4 filing submitted to the SEC. Mason Christopher reported acquisition or exercise transactions in this Form 4 filing.
Krystal Biotech, Inc. director Christopher Mason received equity awards in the form of stock options and restricted stock units. On September 14, 2026 he was granted 1,187 stock options to buy common stock at $340.03 per share, expiring September 13, 2036, and 471 restricted stock units, each representing one share of common stock. Both the options and RSUs vest in full on September 14, 2027, subject to his continued service on the Board of Directors and potential earlier vesting under the company’s Non-Employee Director Compensation Policy. No Rule 10b5-1 trading plan is reported.
Krystal Biotech, Inc. (KRYS) reported that director Daniel Janney received equity awards on September 14, 2026. He was granted 1,187 stock options with an exercise price of $340.03 per share, expiring on September 13, 2036, and 471 restricted stock units. Both the options and RSUs vest in full on September 14, 2027, subject to Mr. Janney’s continued service on the board and earlier vesting conditions described in the company’s Non-Employee Director Compensation Policy. No Rule 10b5-1 trading plan is reported.
Krystal Biotech, Inc. (KRYS) reported that director Julian S. Gangolli received equity awards on September 14, 2026. He was granted 1,187 stock options with an exercise price of $340.03 per share, expiring on September 13, 2036, and 471 restricted stock units. Both the options and RSUs vest in full on September 14, 2027, subject to his continued service on the Board and earlier vesting conditions under the company’s Non-Employee Director Compensation Policy.
Krystal Biotech, Inc. (KRYS) insider Suma Krishnan, a director, President of R&D, and ten percent owner, reported open-market sales of 25,000 shares of common stock on September 4, 2026. The sales were executed in multiple trades at prices within ranges from $353.98 to $366.91 per share and were made under a Rule 10b5-1 trading plan adopted on September 4, 2025, which has now reached its maximum share amount and terminated. Following these transactions, Krishnan continues to hold shares indirectly through several family trusts, including 90,000 shares held by the Krishnan Spousal Trust, 51,010 shares held by the Suma Mani Krishnan Trust, and 50,000 shares held by the Krishnan Family Trust.
Krystal Biotech, Inc. (KRYS) reports that President and CEO, director, and more-than-10% owner Krishnan Krish S sold 25,000 shares of common stock on September 4, 2026 in multiple open-market transactions around the mid-$350s per share, under a Rule 10b5-1 trading plan adopted September 4, 2025 that has now reached its maximum and terminated. He continues to hold shares indirectly through family trusts, including 90,000, 77,710, and 50,000 shares, respectively.
Krystal Biotech, Inc. (KRYS) is the issuer of common stock that Suma Krishnan has notified under Rule 144 of an intention to sell. The notice covers up to 25,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
The shares are described as Founders Shares, acquired from Krystal Biotech on March 31, 2017. The filing lists an aggregate market value for the planned sale of approximately $9,286,750. The form indicates no other Rule 144 sales by the filer in the past three months.
Krystal Biotech, Inc. (KRYS) received a Rule 144 notice from insider Krish Krishnan covering a proposed sale of 25,000 shares of common stock through Morgan Stanley Smith Barney LLC. The shares are identified as founders shares that were originally acquired from the issuer on March 31, 2017.